TPM3 and lung carcinoma: In spite of a 100% sensitivity of TRK IHC in the five lung cancer cases in the current study, it is more efficient from a tissue management and cost perspective to test NSCLC patients with an up-front, panel-based, targeted RNA assay rather than adding an IHC screening for TRK expression.